Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Seattle-Denver Center of Innovation (COIN)

Quick Links
Veterans Crisis Line Badge
My healthevet badge

COIN Investigators & Staff

COIN Investigators


Sridharan Raghavan, MD, PhD
Title: Core Investigator; Career Development Awardee
Associate Professor, University of Colorado School of Medicine
Location: Denver
University of Colorado webpage


See Dr. Raghavan's Dimensions profile that includes: publications, grants, datasets, patents and clinical trials

Return to Top

Research Interests


Dr. Raghavan's publication titles indicate their primary work is care of Veterans
Click to enlarge Word Cloud of Publication key words

Dr. Raghavan's research uses clinical and genetic data to understand how to prevent and treat diabetes and its complications. Veterans are at higher risk for diabetes and have unique risks, so it is an essential issue in the VA.

Though there have been decades of diabetes research, the clinical tools we have to treat diabetes remain relatively blunt. For diabetes prevention, we continue to talk about weight loss and increased physical activity. Still, we need to learn how to tailor that for an individual. It is the same for treating diabetes. We have tried-and-true treatments, which are good. Still, the diversity of people needing treatment exceeds the available treatment methods. One size does not fit all patients.

Only some people can exercise 2.5 hours a week or 30 minutes a day, five days a week. Or lose 7% of their weight over a year. It can be de-motivating. Tailoring prevention and treatment for this large, diverse population is critical.

Dr. Raghavan's collaborations are primarily from the University of Colorado
Click for Research collaboration map

In the coming years, we are looking at medications that may be helpful in prevention and treatment. Medicines that help with weight loss also appear to help prevent diabetes—providing options from behavioral/lifestyle to drugs for the prevention and treatment of diabetes.

There are short-term gains from diabetes prevention and treatment, and there are also long-term benefits. A veteran joining the VA's MOVE Program may lead to weight loss and diabetes prevention. There is also the long-term gain of reduced kidney and heart disease.

When treating pre-diabetes and diabetes, the approach is to try a method for a certain amount of time and see how it works. If it is not helpful, then another approach is tried. For instance, the Veteran might try weight loss through lifestyle change and a new diet for six months. If they are losing weight, then they can continue that approach. If they are not, they may try another method, like exercise. Diabetes is chronic and long-term, and patients' have trouble making choices in the short term for long-term consequences.

Diabetes is a complicated disease, and the role of genetics only adds to the difficulty. Risk factors for diabetes are at once dynamic and static. Dynamic risk factors change for the individual based on lifestyle and environment. Genetics are more fixed. Generally, a person may be born with a genetic predisposition to diabetes that will then interact with what occurs during their lifetime. The gene may or may not be activated based on many factors, including lifestyle and environment. The VA Million Vet Program is attempting to understand this complexity better.

Where is Dr. Raghavan's Research Headed

  1. Improving how the electronic health record (EHR) is used. There is so much information in the EHR, that we have to ask, "can it be used to help predict diabetes?" If risk becomes apparent can a game plan be developed early.
  2. Integrating genetics into a predictive model (combined with the EHR). We do not currently use the genetic information we have to help predict or treat diabetes. For instance, can we adopt treatments based on what we know about a person’s genetics to help determine what medication may work best for weight loss?
  3. Taking the results from clinical trials or studies in one population and generalizing them to Veteran populations. The creation of analytic tools so that any time a study is completed there are methods that can translate or generalize the study, so it applies to Veterans.
The following research fields have been used to summarize Dr. Raghavan's publications and grants.
Publications Grants
Diabetes Cardiovascular
Clinical Research Diabetes
Prevention Heart Disease
Cardiovascular Clinical Research
Heart Disease Prevention
Genetics Atherosclerosis
Nutrition Nutrition
Human Genome Heart Disease - Coronary Heart Disease
Obesity Clinical Trials and Supportive Activities
Heart Disease - Coronary Heart Disease  

Return to Top

Current Grants & Funding

Machine Learning and Longitudinal Analyses of Metformin Response Among Veterans

Type 2 diabetes affects almost a quarter of Veterans. It negatively impacts Veteran health by increasing heart, kidney, and eye disease risks. Diabetes patients represent a diverse population, and the method of selecting the best initial diabetes treatment approach for each patient remains unclear, even though guidelines recommend individualized tailoring of treatment.
The proposed research applies state-of-the-art computational and epidemiologic methods to explore VA clinical data to determine if there are factors that can accurately and reproducibly predict a patient’s risk of developing diabetes complications in the future and their likelihood of responding to metformin, the most commonly used initial treatment for diabetes.
The study will then test whether applying prediction models to guide risk-based selection of initial diabetes treatment might have clinical benefits for patients. The study will inform individualized diabetes care, serve as a model for precision medicine methods to study chronic diseases and contribute to improving Veteran health.
Funder: Veterans Administration
NIH website
Publications of note:
Mendelian randomization study of diabetes and dementia in the Million Veteran Program
Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol
A calibration approach to transportability and data-fusion with observational data
A Diabetes Genetic Risk Score Is Associated With All-Cause Dementia and Clinically Diagnosed Vascular Dementia in the Million Veteran Program

Return to Top

Recent Publications


Billings LK, Jablonski KA, Pan Q, Franks PW, Goldberg RB, Hivert MF, Kahn SE, Knowler WC, Lee CG, Merino J, Huerta-Chagoya A, Mercader JM, Raghavan S, Shi Z, Srinivasan S, Xu J, Florez JC, Udler MS. Increased genetic risk for β-cell failure is associated with β-cell function decline in people with prediabetes. Diabetes. 2024 May 17:db230761. doi: 10.2337/db23-0761. Epub ahead of print.
PMID: 38758294
Learn more about this publication at Dimensions

Yang PK, Jackson SL, Charest BR, Cheng YJ, Sun YV, Raghavan S, Litkowski EM, Legvold BT, Rhee MK, Oram RA, Kuklina EV, Vujkovic M, Reaven PD, Cho K, Leong A, Wilson PWF, Zhou J, Miller DR, Sharp SA, Staimez LR, North KE, Highland HM, Phillips LS; Million Veteran Program. Type 1 Diabetes Genetic Risk in 109,954 Veterans With Adult-Onset Diabetes: The Million Veteran Program (MVP). Diabetes Care. 2024 Apr 12:dc231927. doi: 10.2337/dc23-1927. Epub ahead of print.
PMID: 38608262
Learn more about this publication at Dimensions


Ryskina K, Geng Z, Raghavan S, Waddell KJ, Burke RE. Association Between Timing of Clinical Evaluation by a Physician or Advanced Practitioner and Risk of Rehospitalization in Older Adults Admitted to a Skilled Nursing Facility Following Hospitalization: A Cohort Study. J Am Med Dir Assoc. 2023 Oct 11:S1525-8610(23)00792-2. doi: 10.1016/j.jamda.2023.09.004. Epub ahead of print.
PMID: 37837998
Learn more about this publication at Dimensions

Young KG, McInnes EH, Massey RJ, Kahkoska AR, Pilla SJ, Raghavan S, Stanislawski MA, Tobias DK, McGovern AP, Dawed AY, Jones AG, Pearson ER, Dennis JM; ADA/EASD PDMI. Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review. Commun Med (Lond). 2023 Oct 5;3(1):131. doi: 10.1038/s43856-023-00359-w. PMCID: PMC10551026.
PMID: 37794166
Learn more about this publication at Dimensions

Tobias DK, Merino J, Ahmad A, Aiken C, Benham JL, Bodhini D, Clark AL, Colclough K, Corcoy R, Cromer SJ, Duan D, Felton JL, Francis EC, Gillard P, Gingras V, Gaillard R, Haider E, Hughes A, Ikle JM, Jacobsen LM, Kahkoska AR, Kettunen JLT, Kreienkamp RJ, Lim LL, Männistö JME, Massey R, Mclennan NM, Miller RG, Morieri ML, Most J, Naylor RN, Ozkan B, Patel KA, Pilla SJ, Prystupa K, Raghavan S, Rooney MR, Schön M, Semnani-Azad Z, Sevilla-Gonzalez M, Svalastoga P, Takele WW, Tam CH, Thuesen ACB, Tosur M, Wallace AS, Wang CC, Wong JJ, Yamamoto JM, Young K, Amouyal C, Andersen MK, Bonham MP, Chen M, Cheng F, Chikowore T, Chivers SC, Clemmensen C, Dabelea D, Dawed AY, Deutsch AJ, Dickens LT, DiMeglio LA, Dudenhöffer-Pfeifer M, Evans-Molina C, Fernández-Balsells MM, Fitipaldi H, Fitzpatrick SL, Gitelman SE, Goodarzi MO, Grieger JA, Guasch-Ferré M, Habibi N, Hansen T, Huang C, Harris-Kawano A, Ismail HM, Hoag B, Johnson RK, Jones AG, Koivula RW, Leong A, Leung GKW, Libman IM, Liu K, Long SA, Lowe WL Jr, Morton RW, Motala AA, Onengut-Gumuscu S, Pankow JS, Pathirana M, Pazmino S, Perez D, Petrie JR, Powe CE, Quinteros A, Jain R, Ray D, Ried-Larsen M, Saeed Z, Santhakumar V, Kanbour S, Sarkar S, Monaco GSF, Scholtens DM, Selvin E, Sheu WH, Speake C, Stanislawski MA, Steenackers N, Steck AK, Stefan N, Støy J, Taylor R, Tye SC, Ukke GG, Urazbayeva M, Van der Schueren B, Vatier C, Wentworth JM, Hannah W, White SL, Yu G, Zhang Y, Zhou SJ, Beltrand J, Polak M, Aukrust I, de Franco E, Flanagan SE, Maloney KA, McGovern A, Molnes J, Nakabuye M, Njølstad PR, Pomares-Millan H, Provenzano M, Saint-Martin C, Zhang C, Zhu Y, Auh S, de Souza R, Fawcett AJ, Gruber C, Mekonnen EG, Mixter E, Sherifali D, Eckel RH, Nolan JJ, Philipson LH, Brown RJ, Billings LK, Boyle K, Costacou T, Dennis JM, Florez JC, Gloyn AL, Gomez MF, Gottlieb PA, Greeley SAW, Griffin K, Hattersley AT, Hirsch IB, Hivert MF, Hood KK, Josefson JL, Kwak SH, Laffel LM, Lim SS, Loos RJF, Ma RCW, Mathieu C, Mathioudakis N, Meigs JB, Misra S, Mohan V, Murphy R, Oram R, Owen KR, Ozanne SE, Pearson ER, Perng W, Pollin TI, Pop-Busui R, Pratley RE, Redman LM, Redondo MJ, Reynolds RM, Semple RK, Sherr JL, Sims EK, Sweeting A, Tuomi T, Udler MS, Vesco KK, Vilsbøll T, Wagner R, Rich SS, Franks PW. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med. 2023 Oct 5. doi: 10.1038/s41591-023-02502-5. Epub ahead of print.
PMID: 37794253
Learn more about this publication at Dimensions

Tobias DK, Manning AK, Wessel J, Raghavan S, Westerman KE, Bick AG, Dicorpo D, Whitsel EA, Collins J, Correa A, Cupples LA, Dupuis J, Goodarzi MO, Guo X, Howard B, Lange LA, Liu S, Raffield LM, Reiner AP, Rich SS, Taylor KD, Tinker L, Wilson JG, Wu P, Carson AP, Vasan RS, Fornage M, Psaty BM, Kooperberg C, Rotter JI, Meigs J, Manson JE; TOPMed Diabetes Working Group; National Heart, Lung, and Blood Institute TOPMed Consortium. Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk. Diabetes Care. 2023 Sep 27:dc230805. doi: 10.2337/dc23-0805. Epub ahead of print.
PMID: 37756531
Learn more about this publication at Dimensions

Manning A, Sevilla-González M, Smith K, Wang N, Jensen A, Litkowski E, Kim H, DiCorpo D, Westerman K, Cui J, Liu CT, Yu C, McNeil J, Lacaze P, Chang KM, Tsao P, Phillips L, Goodarzi M, Sladek R, Rotter J, Dupuis J, Florez J, Merino J, Meigs J, Zhou J, Raghavan S, Udler M. Heterogeneous effects on type 2 diabetes and cardiovascular outcomes of genetic variants and traits associated with fasting insulin. Res Sq [Preprint]. 2023 Sep doi: 10.21203/ PMCID: PMC10543499.
PMID: 37790568
Learn more about this publication at Dimensions

Kudron EL, Raghavan S, Lee YM, Lowery JT. Primary care providers' preferences for the communication and management of actionable genomic findings from a research biobank. Genet Med Open. 2023;1(1):100830. doi: 10.1016/j.gimo.2023.100830. Epub 2023 Aug 30. PMCID: PMC10824104.
PMID: 38287920
Learn more about this publication at Dimensions

Litkowski EM, Logue MW, Zhang R, Charest BR, Lange EM, Hokanson JE, Lynch JA, Vujkovic M, Phillips LS, Hauger RL, Lange LA, Raghavan S; VA Million Veteran Program (MVP). Mendelian randomization study of diabetes and dementia in the Million Veteran Program. Alzheimers Dement. 2023 Jul 7. doi: 10.1002/alz.13373. Epub ahead of print.
PMID: 37417779
Learn more about this publication at Dimensions

Litkowski EM, Logue MW, Zhang R, Charest BR, Lange EM, Hokanson JE, Lynch JA, Vujkovic M, Phillips LS, Hauger RL, Lange LA, Raghavan S. Mendelian randomization study of diabetes and dementia in the Million Veteran Program. medRxiv [Preprint]. 2023 Mar 9:2023.03.07.23286526. doi: 10.1101/2023.03.07.23286526. PMCID: PMC10029030.
PMID: 36945581
Learn more about this publication at Dimensions

Kim DH, Jensen A, Jones K, Raghavan S, Phillips LS, Hung A, Sun YV, Li G, Reaven P, Zhou H, Zhou JJ. A platform for phenotyping disease progression and associated longitudinal risk factors in large-scale EHRs, with application to incident diabetes complications in the UK Biobank. JAMIA Open. 2023 Feb 9;6(1):ooad006. doi: 10.1093/jamiaopen/ooad006. PMCID: PMC9912368.
PMID: 36789288
Learn more about this publication at Dimensions



Huang J, Huffman JE, Huang Y, Do Valle Í, Assimes TL, Raghavan S, Voight BF, Liu C, Barabási AL, Huang RDL, Hui Q, Nguyen XT, Ho YL, Djousse L, Lynch JA, Vujkovic M, Tcheandjieu C, Tang H, Damrauer SM, Reaven PD, Miller D, Phillips LS, Ng MCY, Graff M, Haiman CA, Loos RJF, North KE, Yengo L, Smith GD, Saleheen D, Gaziano JM, Rader DJ, Tsao PS, Cho K, Chang KM, Wilson PWF; VA Million Veteran Program; Sun YV, O'Donnell CJ. Genomics and phenomics of body mass index reveals a complex disease network. Nat Commun. 2022 Dec 29;13(1):7973. doi: 10.1038/s41467-022-35553-2. PMCID: PMC9798356.
PMID: 36581621
Learn more about this publication at Dimensions

Zuo S, Josey KP, Raghavan S, Yang F, Juaréz-Colunga E, Ghosh D. Transportability Methods for Time-to-Event Outcomes: Application in Adjuvant Colon Cancer Trials. JCO Clin Cancer Inform. 2022 Dec;6:e2200088. doi: 10.1200/CCI.22.00088.
PMID: 36516368
Learn more about this publication at Dimensions

Yengo L, Vedantam S, Marouli E, Sidorenko J, Bartell E, Sakaue S, Graff M, Eliasen AU, Jiang Y, Raghavan S, et al. A saturated map of common genetic variants associated with human height. Nature. 2022 Oct 12. doi: 10.1038/s41586-022-05275-y. Epub ahead of print.
PMID: 36224396
Learn more about this publication at Dimensions

Litkowski EM, Logue MW, Zhang R, Charest BR, Lange EM, Hokanson JE, Lynch JA, Vujkovic M, Phillips LS, Lange LA, Hauger RL, Raghavan S; VA Million Veteran Program (MVP). A Diabetes Genetic Risk Score Is Associated With All-Cause Dementia and Clinically Diagnosed Vascular Dementia in the Million Veteran Program. Diabetes Care. 2022 Aug 30:dc220105. doi: 10.2337/dc22-0105. Epub ahead of print.
PMID: 36041056
Learn more about this publication at Dimensions

Tcheandjieu C, Zhu X, Hilliard AT, Clarke SL, Napolioni V, Ma S, Lee KM, Fang H, Chen F, Lu Y, Tsao NL, Raghavan S, Koyama S, Gorman BR, Vujkovic M, Klarin D, Levin MG, Sinnott-Armstrong N, Wojcik GL, Plomondon ME, Maddox TM, Waldo SW, Bick AG, Pyarajan S, Huang J, Song R, Ho YL, Buyske S, Kooperberg C, Haessler J, Loos RJF, Do R, Verbanck M, Chaudhary K, North KE, Avery CL, Graff M, Haiman CA, Le Marchand L, Wilkens LR, Bis JC, Leonard H, Shen B, Lange LA, Giri A, Dikilitas O, Kullo IJ, Stanaway IB, Jarvik GP, Gordon AS, Hebbring S, Namjou B, Kaufman KM, Ito K, Ishigaki K, Kamatani Y, Verma SS, Ritchie MD, Kember RL, Baras A, Lotta LA; Regeneron Genetics Center; CARDIoGRAMplusC4D Consortium; Biobank Japan; Million Veteran Program, Kathiresan S, Hauser ER, Miller DR, Lee JS, Saleheen D, Reaven PD, Cho K, Gaziano JM, Natarajan P, Huffman JE, Voight BF, Rader DJ, Chang KM, Lynch JA, Damrauer SM, Wilson PWF, Tang H, Sun YV, Tsao PS, O'Donnell CJ, Assimes TL. Large-scale genome-wide association study of coronary artery disease in genetically diverse populations. Nat Med. 2022 Aug 1. doi: 10.1038/s41591-022-01891-3. Epub ahead of print.
PMID: 35915156
Learn more about this publication at Dimensions

O'Sullivan JW, Raghavan S, Marquez-Luna C, Luzum JA, Damrauer SM, Ashley EA, O'Donnell CJ, Willer CJ, Natarajan P; American Heart Association Council on Genomic and Precision Medicine; Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2022 Jul 18:101161CIR0000000000001077. doi: 10.1161/CIR.0000000000001077. Epub ahead of print.
PMID: 35862132
Learn more about this publication at Dimensions

Josey KP, Yang F, Ghosh D, Raghavan S. A calibration approach to transportability and data-fusion with observational data. Stat Med. 2022 Jul 18. doi: 10.1002/sim.9523. Epub ahead of print.
PMID: 35848098
Learn more about this publication at Dimensions

Raghavan S, Huang J, Tcheandjieu C, Huffman JE, Litkowski E, Liu C, Ho YA, Hunter-Zinck H, Zhao H, Marouli E, North KE; VA Million Veteran Program, Lange E, Lange LA, Voight BF, Gaziano JM, Pyarajan S, Hauser ER, Tsao PS, Wilson PWF, Chang KM, Cho K, O'Donnell CJ, Sun YV, Assimes TL. A multi-population phenome-wide association study of genetically-predicted height in the Million Veteran Program. PLoS Genet. 2022 Jun 2;18(6):e1010193. doi: 10.1371/journal.pgen.1010193. PMCID: PMC9162317.
PMID: 35653334
Learn more about this publication at Dimensions

Edward JA, Josey K, Bahn G, Caplan L, Reusch JEB, Reaven P, Ghosh D, Raghavan S. Heterogeneous treatment effects of intensive glycemic control on major adverse cardiovascular events in the ACCORD and VADT trials: a machine-learning analysis. Cardiovasc Diabetol. 2022 Apr 27;21(1):58. doi: 10.1186/s12933-022-01496-7.
PMID: 35477454
Learn more about this publication at Dimensions

Raghavan S, Warsavage T, Liu WG, Raffle K, Josey K, Saxon DR, Phillips LS, Caplan L, Reusch JEB. Trends in Timing of and Glycemia at Initiation of Second-line Type 2 Diabetes Treatment in U.S. Adults. Diabetes Care. 2022 Mar 28:dc212492. doi: 10.2337/dc21-2492. Epub ahead of print.
PMID: 35344584
Learn more about this publication at Dimensions

Kim J, Jensen A, Ko S, Raghavan S, Phillips LS, Hung A, Sun Y, Zhou H, Reaven P, Zhou JJ. Systematic Heritability and Heritability Enrichment Analysis for Diabetes Complications in UK Biobank and ACCORD Studies. Diabetes. 2022 Feb 8:db210839. doi: 10.2337/db21-0839. Epub ahead of print.
PMID: 35133398
Learn more about this publication at Dimensions

Lu B, Posner D, Vassy JL, Ho YL, Galloway A, Raghavan S, Honerlaw J, Tarko L, Russo J, Qazi S, Orkaby AR, Tanukonda V, Djousse L, Gaziano JM, Gagnon DR, Cho K, Wilson PWF. Prediction of Cardiovascular and All-Cause Mortality After Myocardial Infarction in US Veterans. Am J Cardiol. 2022 Jan 18:S0002-9149(21)01265-0. doi: 10.1016/j.amjcard.2021.12.036. Epub ahead of print.
PMID: 35063273
Learn more about this publication at Dimensions



Wu P, Moon JY, Daghlas I, Franco G, Porneala BC, Ahmadizar F, Richardson TG, Isaksen JL, Hindy G, Yao J, Sitlani CM, Raffield LM, Yanek LR, Feitosa MF, Cuadrat RRC, Qi Q, Arfan Ikram M, Ellervik C, Ericson U, Goodarzi MO, Brody JA, Lange L, Mercader JM, Vaidya D, An P, Schulze MB, Masana L, Ghanbari M, Olesen MS, Cai J, Guo X, Floyd JS, Jäger S, Province MA, Kalyani RR, Psaty BM, Orho-Melander M, Ridker PM, Kanters JK, Uitterlinden A, Davey Smith G, Gill D, Kaplan RC, Kavousi M, Raghavan S, Chasman DI, Rotter JI, Meigs JB, Florez JC, Dupuis J, Liu CT, Merino J. Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol. Diabetes Care. 2021 Nov 17:dc211284. doi: 10.2337/dc21-1284. Epub ahead of print.
PMID: 34789503

Raghavan S, Josey K, Bahn G, Reda D, Basu S, Berkowitz SA, Emanuele N, Reaven P, Ghosh D. Generalizability of heterogeneous treatment effects based on causal forests applied to two randomized clinical trials of intensive glycemic control. Ann Epidemiol. 2021 Jul 16:S1047-2797(21)00212-X. doi: 10.1016/j.annepidem.2021.07.003. Epub ahead of print.
PMID: 34280545

Stanislawski MA, Litkowski E, Raghavan S, Harrall KK, Shaw J, Glueck DH, Lange EM, Dabelea D, Lange LA. Genetic Risk Score for Type 2 Diabetes and Traits Related to Glucose-Insulin Homeostasis in Youth: The Exploring Perinatal Outcomes Among Children (EPOCH) Study. Diabetes Care. 2021 Jul 13:dc210464. doi: 10.2337/dc21-0464. Epub ahead of print.
PMID: 34257098

Stanislawski MA, Litkowski E, Fore R, Rifas-Shiman SL, Oken E, Hivert MF, Lange EM, Lange LA, Dabelea D, Raghavan S. Genetic Interactions with Intrauterine Diabetes Exposure in Relation to Obesity: The EPOCH and Project Viva Studies. Pediatr Rep. 2021 Jun 1;13(2):279-288. doi: 10.3390/pediatric13020036.
PMID: 34205853

Josey KP, Berkowitz SA, Ghosh D, Raghavan S. Transporting experimental results with entropy balancing. Stat Med. 2021 May 20. doi: 10.1002/sim.9031. Epub ahead of print.
PMID: 34018204

Kini V, Mosley B, Raghavan S, Khazanie P, Bradley SM, Magid DJ, Ho PM, Masoudi FA. Differences in High- and Low-Value Cardiovascular Testing by Health Insurance Provider. J Am Heart Assoc. 2021 Jan 28:e018877. doi: 10.1161/JAHA.120.018877. Epub ahead of print.
PMID: 33506684

Raghavan S, Jablonski K, Delahanty LM, Maruthur NM, Leong A, Franks PW, Knowler WC, Florez JC, Dabelea D; Diabetes Prevention Program Research Group. Interaction of diabetes genetic risk and successful lifestyle modification in the Diabetes Prevention Program. Diabetes Obes Metab. 2021 Jan 4. doi: 10.1111/dom.14309. Epub ahead of print. PMID: 33394545



Salahuddin T, Richardson V, McNeal DM, Henderson K, Hess PL, Raghavan S, Saxon DR, Valle JA, Waldo SW, Ho PM, Schwartz GG. Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program. Diabetes Obes Metab. 2021 Jan;23(1):97-105. doi: 10.1111/dom.14193. Epub 2020 Oct 3. PMID: 32902128

Raghavan S, Ho YL, Vassy JL, Posner D, Honerlaw J, Costa L, Phillips LS, Gagnon DR, Wilson PWF, Cho K. Optimizing Atherosclerotic Cardiovascular Disease Risk Estimation for Veterans With Diabetes Mellitus. Circ Cardiovasc Qual Outcomes. 2020 Aug 31:CIRCOUTCOMES120006528. doi: 10.1161/CIRCOUTCOMES.120.006528. Epub ahead of print. PMID: 32862698

Raghavan S, Liu WG, Berkowitz SA, Barón AE, Plomondon ME, Maddox TM, Reusch JEB, Ho PM, Caplan L. Association of Glycemic Control Trajectory with Short-Term Mortality in Diabetes Patients with High Cardiovascular Risk: a Joint Latent Class Modeling Study. J Gen Intern Med. 2020 Aug;35(8):2266-2273. doi: 10.1007/s11606-020-05848-5. Epub 2020 Apr 24. PMCID: PMC7403288. PMID: 32333313

Raghavan S, Xu K, Coffman CJ, Pabich S, Edelman D, Voils CI. Associations of Diabetes Genetic Risk Counseling with Incident Diabetes and Weight: 5-Year Follow-up of a Randomized Controlled Trial. J Gen Intern Med. 2020 Mar;35(3):944-946. doi: 10.1007/s11606-019-05126-z. Epub 2019 Jul 16. PMCID: PMC7080941. PMID: 31313118

Return to Top

Media (Presentations, webinars, podcasts, etc.


Podcast: What does height have to do with disease risk

On this episode of Health Findings in Focus our Investigator Dr. Sridharan Raghavan talks about his recent paper, “A multi-population phenome-wide association study of genetically-predicted height in the Million Veteran Program”. The paper draws on data from the VA Million Veteran Program, which is a national research program to learn how genes, lifestyle, and military exposures affect health and illness. Listen to learn how height might play a role in certain diseases and what this research means.
Learn more about the VA Million Veteran Program (MVP)

Listen to: What does height have to do with disease risk


Human Medical Genetics and Genomics Presentation by Dr. Sridharan Raghavan

11 March 2021 - Dr. Sridharan Raghavan gave a presentation titled, "What clinical data linked to genetics can teach us about diabetes complications and height as a disease risk factor." Unfortunately, there is no recording to share.